6 research outputs found
Nutrient Status and Yield of French marigold as Influenced by Application of Spent Mushroom Compost, Biofertilizer and MKP Foliar Application
No full textAn experiment was carried out in open field condition during the year 2018-19 to ascertain the effect of spent mushroom compost, biofertilizers and MKP foliar application on nutrient status, yield and profitability of French marigold. The experiment was laid out in Completely Randomized Block Design (CRBD) and comprised of twenty three treatments replicated thrice. The highest available soil nitrogen content (259.95 Kg/ha), available soil P (33.23 Kg/ha) and available soil potassium content (244.60 Kg/ha) was recorded with Control (100% RDF).Maximum total leaf nitrogen (1.367%), leaf phosphorus (0.433%) and leaf potassium content (1.88%) was recorded with treatment 75% RDF + spent mushroom compost + biofertilizers + 1% foliar spray of MKP (T9) whereas, the lowest total leaf nitrogen content (1.103%), leaf phosphorus content (0.313%) and total leaf K (1.33 %) was recorded with no fertilizer application (Farmers practice). Plants treated with 75% RDF + Biofertilizers + 1% foliar spray of MKP (T8) recorded the highest benefit cost ratio (2.81:1) closely followed by benefit cost ratio of 2.54 in 100% RDF whereas lowest benefit cost ratio (0.36:1) was recorded in the treatment T17 comprising 25 % RDF + Spent mushroom compost (1 kg/m2).Highest chlorophyll content (48.89%) was recorded with T8
Yield Potentiality and Economic Profitability as Influenced by Conjoint Application of Spent Mushroom Compost, Biofertilizers and Mono Potassium Phosphate (MKP) in Marigold
No full textThe present investigation was carried out under open field conditions during the year 2018-19 to ascertain the influence of spent mushroom compost, biofertilizers and foliar application of water soluble fertilizer, Mono Potassium Phosphate (MKP) on flower yield and economics of French marigold ‘Local’. The results revealed that the overall cost of cultivation as well as the economics of marigold flower production was significantly influenced by various Integrated nutrient management (INM) schedules. French marigold ‘Local’ plants supplied with 75% RDF + Spent mushroom compost (1 kg/m2) + Biofertilizers + 1% foliar spray of MKP (00:52:34) produced maximum yield of saleable flowers (25000 Kg/ha) followed by 75% RDF + Biofertilizers + 1% foliar spray of MKP (23000 Kg/ha) which was significantly superior over the 100% RDF recording 20000 Kg/ha flower yield. Both the above mentioned treatments also recorded maximum net returns of Rs.339171.60/ha. The highest benefit : cost (B: C) ratio of 2.81 was recorded with the treatment 75% RDF + Biofertilizers + 1% foliar spray of MKP
Marital unions, comparative study : French law and Libyan law
No full textLe droit français et le droit libyen reposent sur des principes foncièrement différents. Le premier, fondé sur la laïcité, prône l'égalité homme-femme. Le second, de tradition religieuse n'est pas favorable à ce principe, la prédominance masculine en est le trait caractéristique. Cette distinction se voit tout au long de notre étude. Dans une première partie nous traitons les différentes formes de couples que connaissent les deux systèmes ainsi que les effets de nature aussi bien personnelle que patrimoniale qui en résultent. Cela comprend notamment l'exercice de l'autorité parentale et la contribution aux frais de ménage. Dans la seconde partie, il est question de la dissolution du couple et des conséquences qu'elle produit, personnelles comme patrimoniales. Malgré les différences entre les deux systèmes, on observe des difficultés de part et d'autre relatives à l'existence et à la dissolution du couple. Le système français est très attaché aux principes de liberté, égalité ; le système libyen est d'avantage protectionniste. D'une manière générale, les unions conjugales sont toujours le reflet d'une culture et des évolutions dans une société.The author deals with different forms of marital unions in French and Libyan law. The main questions treated in the thesis are the consequences of marital life and its dissolution
Effect of Nano Urea Application and Mineral Nutrition on Vegetative, Flowering and Yield of French Marigold (Tagetes patula L.)
No full textTagetes patula L. is one of the most popular and commercial loose flower crops of Jammu, India. Popularly known as the city of temples, the Jammu region witnesses a huge demand for marigold flowers for garland making, offerings in temples and other decorative purposes during various festive occasions. As a result, the production of flowers in Jammu alone cannot meet the ever-increasing demand, and flowers worth lakhs need to be procured from neighbouring states. This study was conducted with the aim of exploring and elucidating the potential impact of different concentrations of nano-urea on vegetative growth, flowering, fruiting, and yield. The study was conducted at the Experimental Farm, Division of Floriculture and Landscaping, Sher-e-Kashmir University of Agricultural Sciences and Technology, Chatha during the years 2022-2023&2023-24. The experiment was laid out in Complete Randomized Block Design with three replication and fifteen treatments viz., T1 =100% RDF (Control i.e. 200 kg N, 100 kg P2O5 and 100 kg K2O/ha);T2 = 100% RDF + 1ml/l nano urea foliar application;T3 =100% RDF + 1.5 ml/l nano urea foliar application;T4 =100% RDF + 2 ml/l nano urea soil application;T5 = 100% RDF + 4 ml/l nano urea soil application;T6 = 75% RDF;T7=75% RDF + 1ml/l nano urea foliar application;T8 = 75% RDF + 1.5 ml/l nano urea foliar application;T9 = 75% RDF + 2 ml/l nano urea soil application;T10 = 75% RDF + 4 ml/l nano urea soil application;T11 = 50 % RDF;T12 = 50 % RDF + 1 ml/l nano urea foliar application;T13 = 50 % RDF + 1.5ml/l nano urea foliar application;T14 = 50 % RDF + 2 ml/l nano urea soil application;T15 = 50 % RDF + 4 ml/l nano urea soil application. The results revealed that the data revealed that maximum plant height (84.36 cm), plant spread (65.34 cm), number of laterals (20.40) and Chlorophyll content (48.38) with the application of 100% RDF + 1.5ml/L nano urea foliar application. The pooled data furthermore, revealed the maximum number of flowers per plant (148.06), flower diameter (5.93 cm), flowering duration (56.22 days), weight of flower (5.01 g), flower yield per plant (0.74 kg), the cost: benefit ratio during the year 2022-2023 and 2023-2024 (4.98 and 5.77, respectively) were recorded maximum in the treatment combination of 75% RDF + 1.5ml/L nano urea foliar application
Conjoint Application of INM Modules on Vegetative, Flowering, and Seed Yield in French marigold
No full textThe present investigation was carried out at Sher-e-Kashmir University of Agricultural Sciences and Technology, Chatha, Jammu during 2018-19. The experiment was laid out in Randomized Block Design and comprised of twenty-three treatments replicated thrice. Among the various treatments, maximum plant height (90.10 cm) and highest number of laterals (21.89) were recorded with treatment T7 comprising of 75 % RDF + Spent mushroom compost (1 kg/m2) + 1% foliar spray of MKP (00:52:34). Lesser number of days taken to 50% flowering (70.22 days), number of flowers/plant (86.78), maximum flower diameter (6.20g), weight of flower (5.78 g), flower yield per plant (500 g), seed yield/plant (105.91 g), 1000 seed weight (11.67g) was recorded with the treatment of 75 % RDF + Spent mushroom compost (1 kg/m2) + 1% foliar spray of MKP (T9). Maximum plant spread (68.44 cm) was recorded with treatment comprising of 75 % RDF + Spent mushroom compost (1 kg/m2) + Biofertilizers (T6). However, minimum electrical conductivity of seed leachate (0.688 µmhos/cm/g) was recorded with 25 % RDF + Spent mushroom compost (1 kg/m2) + Biofertilizers (T20). The effects of treatments on flowering duration (days) and shoot: root ratio was found to be non-significant
Neoantigen-directed immune escape in lung cancer evolution
No full textThe interplay between an evolving cancer and a dynamic immune microenvironment remains unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell lung cancers using RNA sequencing and histopathology-assessed tumour-infiltrating lymphocyte estimates. Immune infiltration varied both between and within tumours, with different mechanisms of neoantigen presentation dysfunction enriched in distinct immune microenvironments. Sparsely infiltrated tumours exhibited a waning of neoantigen editing during tumour evolution, indicative of historical immune editing, or copy-number loss of previously clonal neoantigens. Immune-infiltrated tumour regions exhibited ongoing immunoediting, with either loss of heterozygosity in human leukocyte antigens or depletion of expressed neoantigens. We identified promoter hypermethylation of genes that contain neoantigenic mutations as an epigenetic mechanism of immunoediting. Our results suggest that the immune microenvironment exerts a strong selection pressure in early-stage, untreated non-small-cell lung cancers that produces multiple routes to immune evasion, which are clinically relevant and forecast poor disease-free survival.sponsorship: We thank the members of the TRACERx consortium for participating in this study. C.S. is Royal Society Napier Research Professor. C.S. is supported by the Francis Crick Institute, which receives its core funding from the Medical Research Council (FC001169), the Wellcome Trust (FC001169), and Cancer Research UK (FC001169). C.S. is funded by Cancer Research UK (TRACERx and CRUK Cancer Immunotherapy Catalyst Network), the CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C), the Rosetrees and Stoneygate Trusts, NovoNordisk Foundation (ID 16584), the Breast Cancer Research Foundation (BCRF), the European Research Council Consolidator Grant (FP7-THESEUS-617844), European Commission ITN (FP7-PloidyNet-607722), Chromavision (this project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 665233), National Institute for Health Research (NIHR), the University College London Hospitals Biomedical Research Centre (BRC) and the Cancer Research UK University College London Experimental Cancer Medicine Centre. N.M. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (211179/Z/18/Z), and also receives funding from CRUK Lung Cancer Centre of Excellence, Rosetrees and the University College London Hospitals Biomedical Research Centre (BRC) and the Cancer Research UK University College London Experimental Cancer Medicine Centre. E.L.C., J.D. and P.V.L. are supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001202), the UK Medical Research Council (FC001202), and the Wellcome Trust (FC001202). P.V.L. is a Winton Group Leader in recognition of the Winton Charitable Foundation's support towards the establishment of The Francis Crick Institute. J.D. is a postdoctoral fellow of the Research Foundation -Flanders (FWO). S.A.Q. is funded by a CRUK Senior Cancer Research Fellowship (C36463/A22246), a CRUK Biotherapeutic Program Grant (C36463/A20764), the Cancer Immunotherapy Accelerator Award (CITA-CRUK) (C33499/A20265) and Rosetrees. M.T. received funding from the People Programme Marie Curie Actions (FP7/2007-2013/WHRI-ACADEMY-608765) and the Danish Council for Strategic Research (1309-00006B). The TRACERx study (Clinicaltrials. gov no: NCT01888601) is sponsored by University College London (UCL/12/0279) and has been approved by an independent Research Ethics Committee (13/LO/1546). TRACERx is funded by Cancer Research UK (C11496/A17786) and coordinated through the Cancer Research UK and UCL Cancer Trials Centre. For the RRBS methylation data, we acknowledge technical support from the CRUK-UCL Centre-funded Genomics and Genome Engineering Core Facility of the UCL Cancer Institute and grant support from the NIHR BRC (BRC275/CN/SB/101330). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The results published here are based in part upon data generated by The Cancer Genome Atlas pilot project established by the NCI and the National Human Genome Research Institute. The data were retrieved through database of Genotypes and Phenotypes (dbGaP) authorization (accession number phs000178.v9.p8). Information about TCGA and the constituent investigators and institutions the TCGA research network can be found at http://cancergenome.nih.gov/. (Francis Crick Institute - Medical Research Council|FC001169, Wellcome Trust|FC001169, Wellcome Trust|211179/Z/18/Z, Wellcome Trust|FC001202, Cancer Research UK|FC001169, Cancer Research UK|C11496/A17786, Cancer Research UK (TRACERx), CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C), Rosetrees Trust, Stoneygate Trust, NovoNordisk Foundation|16584, Breast Cancer Research Foundation (BCRF), European Research Council Consolidator Grant|FP7-THESEUS-617844, European Commission ITN|FP7-PloidyNet-607722, Chromavision (European Union's Horizon 2020 research and innovation programme)|665233, National Institute for Health Research (NIHR), University College London Hospitals Biomedical Research Centre (BRC), Cancer Research UK University College London Experimental Cancer Medicine Centre, Royal Society|211179/Z/18/Z, Rosetrees, Francis Crick Institute - Cancer Research UK|FC001202, UK Medical Research Council|FC001202, Winton Charitable Foundation, CRUK Senior Cancer Research Fellowship|C36463/A22246, CRUK Biotherapeutic Program Grant|C36463/A20764, Cancer Immunotherapy Accelerator Award (CITA-CRUK)|C33499/A20265, People Programme Marie Curie Actions|FP7/2007-2013/WHRI-ACADEMY-608765, Danish Council for Strategic Research|1309-00006B, University College London|UCL/12/0279, CRUK-UCL Centre, NIHR BRC|BRC275/CN/SB/101330, Cancer Research UK (CRUK Cancer Immunotherapy Catalyst Network), Cancer Research UK|23896, Cancer Research UK|19278, Cancer Research UK|24314, Cancer Research UK|20466, Cancer Research UK|28990, Cancer Research UK|20764, Cancer Research UK|16463, Cancer Research UK|20465, Cancer Research UK|17786, Cancer Research UK|21999, Cancer Research UK|24956, Cancer Research UK; Versus Arthritis|22246, Cancer Research UK; Versus Arthritis|20265, Medical Research Council|MC_UP_1203/1, National Institute for Health Research|CL-2015-18-009, National Institute for Health Research|CL-2015-17-002, Novo Nordisk Fonden|NNF15OC0016584, Rosetrees|M179, Rosetrees|M630, The Francis Crick Institute|10169, The Francis Crick Institute|10202, The Francis Crick Institute|10002, The Francis Crick Institute|10233, Wellcome Trust|107963/Z/15/Z, Wellcome Trust|211179/Z/18/Z)status: Publishe
